(LONN) Lonza - Ratings and Ratios

Lonza Group AG (SW:LONN) is a global leader in the development and manufacturing of pharmaceutical, biotech, and nutrition products. With operations spanning Europe, the Americas, Asia, Australia, and New Zealand, the company serves a diverse range of markets through its four core segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Lonzas Biologics segment specializes in contract development and manufacturing of biopharmaceuticals, supporting clinical and commercial manufacturing needs across the entire product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment offers integrated development and manufacturing services for small molecule drug substances and intermediates, with expertise in particle engineering and drug product packaging. The Cell & Gene segment focuses on industrializing manufacturing processes for cell and gene therapies, providing contract development and manufacturing services, regulatory support, and enabling technologies such as the Cocoon platform for patient-scale cell therapy manufacturing. Additionally, this segment supplies specialty raw materials for cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing applications. The Capsules & Health Ingredients segment provides capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers.

Founded in 1897 and headquartered in Basel, Switzerland, Lonza Group AG has established itself as a key player in the biotechnology and pharmaceutical manufacturing industries. Its extensive portfolio of services and products is supported by cutting-edge technologies and a commitment to innovation, enabling the company to meet the evolving needs of its global customer base. Lonzas capabilities extend from early-stage development to commercial-scale manufacturing, making it a trusted partner for companies across the biopharma and nutrition sectors.

Over the next three months, Lonza Group AG (SW:LONN) is expected to experience moderate price fluctuations, influenced by both technical and fundamental factors. From a technical perspective, the stock is currently trading near its 20-day SMA (538.02) but below its 50-day (560.21) and 200-day (547.40) SMAs, indicating potential short-term consolidation. The ATR of 17.83 suggests manageable volatility. Fundamentally, the companys strong RoE (18.43) and forward P/E (31.65) signal positive growth expectations, though the current P/E (60.72) reflects elevated valuations. The 3-month forecast anticipates the stock to trade in a range between 510 and 570, with potential upside driven by strong earnings momentum and continued demand for its services in the biopharma sector.